X-37
X-37 discovers novel drug candidates by applying artificial intelligence to large chemical libraries, accelerating early-stage pharmaceutical discovery. The company uses AI-driven virtual screening and molecular modelling to identify and prioritize compounds against high-value biological targets. Its approach combines deep learning models and cheminformatics to search vast compound spaces and predict likely binders. X-37 operates as a pharmaceutical discovery and development company (B2B), partnering with or supplying candidates to biotech and pharma organizations. The company targets early drug discovery workflows to reduce time and cost for preclinical candidate identification.
X-37
X-37 discovers novel drug candidates by applying artificial intelligence to large chemical libraries, accelerating early-stage pharmaceutical discovery. The company uses AI-driven virtual screening and molecular modelling to identify and prioritize compounds against high-value biological targets. Its approach combines deep learning models and cheminformatics to search vast compound spaces and predict likely binders. X-37 operates as a pharmaceutical discovery and development company (B2B), partnering with or supplying candidates to biotech and pharma organizations. The company targets early drug discovery workflows to reduce time and cost for preclinical candidate identification.